Radiation therapy of cardiac sarcomas

Purpose: Primary cardiac sarcomas represent less than 10 yearly cases in France. Their median survival is approximately 18 months. The treatment consists of surgery when possible. The role of chemotherapy and radiation therapy is controversial, especially with respect to limiting cardiac radiation dose that is theoretically incompatible with the requirement of a tumoricidal dose for sarcoma. A recent series of 124 cases of the French Sarcoma Group suggested a benefit of radiation therapy on progression-free survival. Patients and methods: The dosimetric data of 12 patients were analyzed. Results: There was variety in radiotherapy modalities and definition of target volumes, doses and techniques are evolving more conformal plans. Irradiation appeared feasible with conventional fractionation with respect to toxicities (although probably underestimated due to short follow-up and dismal prognosis) and previously demonstrated benefit of radiotherapy for primitive cardiac sarcomas. Conclusion: A scheme of 45. Gy in 1.8. Gy per fraction to a preoperative volume with an additional dose of 14. Gy in 7 fractions on areas at risk or residual disease and margins 1. cm, may be proposed based on the preliminary data of this study. Intensity modulated radiotherapy with daily cone-beam CT-scanner should be evaluated. © 2014 Société française de radiothérapie oncologique (SFRO).